You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer

https://doi.org/10.1136/jclinpath-2015-203493

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors Planning the study: JR and SV. Conducting: JR, SN-M, IYG, JMSB, HN and SV. Reporting: JR, SN-M, IYG and SV.

    • Competing interests SV: Advisory Board—Roche, EISAI, Amgen, Novartis, Astra Zeneca. JMSB: consulting or advisory role. Entity: Insight Genetics and BioNTech GmbH. Patents, royalties and other intellectual property. Entity: we have filed two patents relating to biomarkers in breast cancer.

    • Ethics approval The institutional review board approved this work. None of the guidelines supplied by the EQUATOR Network are appropriate for this study: retrospective pathological analysis and chart review.

    • Provenance and peer review Not commissioned; externally peer reviewed.